Antisynthetase syndrome-associated interstitial lung disease
Conditions
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Tocilizumab group: 1. Aged >=18 years, meeting the 2017 EULAR/ACR classification criteria for anti-synthetase syndrome; 2.Tocilizumab group: 2.HRCT confirmed ILD; 3.Tocilizumab group: 3.Patients who remain active after hormone therapy and have failed to respond to both hormone therapy and one first-line immunosuppressant (methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, baricitinib, upadacitinib, etc.); 4.Tocilizumab group: 4.Patients who have received tocilizumab and have signed the informed consent form for tocilizumab use; 5.Control group: 1. Aged >=18 years, meeting the 2017 EULAR/ACR classification criteria for anti-synthetase syndrome; 6.Control group: 2.HRCT confirmed ILD; 7.Control group: 3.Patients who remain active after hormone therapy and have failed to respond to hormone therapy and one first-line immunosuppressant (mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, baricitinib, upadacitinib, etc.);
Exclusion criteria
Exclusion criteria: 1.Tocilizumab group:1.Pregnant or lactating women; 2.Tocilizumab group: 2.Patients with psychiatric disorders; 3.Tocilizumab group: 3.Patients who have undergone lung transplantation; 4.Tocilizumab group: 4.Patients who did not receive tocilizumab; 5.Control group: 1.Pregnant or lactating women; 6.Control group: 2.Patients with psychiatric disorders; 7.Control group: 3. Patients who have undergone lung transplantation; 8.Control group: 4.Patients who received tocilizumab;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Baseline vs symptom change over at least 12-24 weeks;Baseline vs. at least 12-24 weeks of symptom and CT changes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes before and after IL-6 treatment;Changes in ferritin before and after treatment;Changes before and after FVC treatment;Changes in lactate dehydrogenase before and after treatment;Changes in creatine kinase before and after treatment;Changes in CRP before and after treatment; | — |
Countries
China
Contacts
Public ContactHu Yinan
China-Japan Friendship Hospital
Outcome results
None listed